Skip to main content

ManoMotion AB has been granted over € 2 M from EU

Press release   •   Apr 16, 2019 12:00 CEST

ManoMotion has been granted funding of almost 2.2 Million € under the EU program Horizon 2020. The project is divided 50/50 between market development and for developing our existing, patented technology. The contribution was granted in competition with 1752 European companies applying, out of which only 64 were granted funds. To us this a verification that ManoMotion’s technology will have impact on the future Europe.

ManoMotion is the leading company in hand tracking and gesture analysis by providing a patented framework for realtime 3D gestural analysis with a standard RGB camera found in everyday smartphones.

ManoMotion’s is the first software solution that creates realistic real-time hand understanding, gesture control & hand-to-object interaction in augmented and virtual reality environments. The company is on a mission to interpret human intent and make technology more natural and intuitive.

With one billion AR enabled smartphones on the market and increasing sales of AR and VR-glasses there is a huge market space where Manomotion is leading the development.

For more information, please contact CEO Lars Österberg at +46 739 739 063 or Chairman of the Board Sven Löfquist at telephone nr +46 708 175 204.

ManoMotion is the leading company in hand tracking and gesture analysis in 3D-space by using a standard RGB camera and proprietary AI based software package that can run on any smart device. ManoMotion brings unparalleled intuition in human-computer interactions (HCI), refined through 10 years of research and development in gesture technology. AR/VR-glasses as well as AR software in smart phones and other gadgets is seeking true 3D gesture control for innovative applications, a huge market space where Manomotion is leading the development.

Comments (0)

Add comment

Comment

By submitting the comment you agree that your personal data will be processed according to Mynewsdesk's Privacy Policy.